Los Angeles Capital Management
RLMD icon

Los Angeles Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Los Angeles Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,877
Closed -$29.2K – 1218
2023
Q2 		$29.2K Buy
11,877
+127
+1% +$351 ﹤0.01% 1146
2023
Q1 		$26.6K Sell
11,750
-901
-7% -$3.11K ﹤0.01% 1150
2022
Q4 		$44.2K Buy
12,651
+6,600
+109% +$58K ﹤0.01% 1179
2022
Q3 		$224K Buy
+6,051
New +$168K ﹤0.01% 1154

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Los Angeles Capital Management's RLMD Position: Q3 2023 in Review

Los Angeles Capital Management sold out of Relmada Therapeutics (RLMD) in Q3 2023, closing a stake of 11,877 shares — an estimated $29.2K sold.

Los Angeles Capital Management first reported a position in RLMD in Q3 2022 and held it in 4 quarters. The position peaked at $224K in Q3 2022. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2023.

  • Los Angeles Capital Management reported no remaining Relmada Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Los Angeles Capital Management sold 11,877 Relmada Therapeutics shares in Q3 2023, an estimated $29.2K.
  • Los Angeles Capital Management first reported a position in Relmada Therapeutics in Q3 2022 and held it in 4 quarters.
  • Los Angeles Capital Management's Relmada Therapeutics position peaked at $224K in Q3 2022.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2023.

Based on Los Angeles Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.